Showing results (431-440 of 470) with videos related to

Sort By:
Pageof 47
Science Signaling|November 14, 2019
The ALK-1/SMAD/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary arterial hypertensionMasato Morikawa, Yoshihide Mitani, Katarina Holmborn, et al.
Blood Advances|February 23, 2018
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemiaTibor J Kovacsovics, Alice Mims, Mohamed E Salama, et al.
Leukemia|July 6, 2007
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialE Tavernier, J-M Boiron, F Huguet, et al.
Blood|February 21, 2004
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleMichele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2004
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trialXavier Thomas, Jean-Michel Boiron, Françoise Huguet, et al.
Advances in Hematology|November 24, 2025
Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer CentersConnor Willis, Andre Hejazi, Vonetta L Williams, et al.
Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Blood Advances|September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myelomaLuciano J Costa, Faith E Davies, Gregory P Monohan, et al.
Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Pageof 47